VLDL Cholesterol

Cholesterol which is contained in or bound to very low density lipoproteins (VLDL). High circulating levels of VLDL cholesterol are found in HYPERLIPOPROTEINEMIA TYPE IIB. The cholesterol on the VLDL is eventually delivered by LOW-DENSITY LIPOPROTEINS to the tissues after the catabolism of VLDL to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LDL.

Also Known As:

Networked: 525 relevant articles (29 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Asemi, Zatollah: 11 articles (01/2022 - 01/2017)
2.	Jamilian, Mehri: 4 articles (01/2020 - 03/2017)
3.	Naik, Prakash Ramachandra: 4 articles (02/2019 - 12/2017)
4.	Taghizadeh, Mohsen: 4 articles (12/2017 - 01/2017)
5.	Hirowatari, Yuji: 3 articles (01/2021 - 11/2010)
6.	Li, Yan: 3 articles (11/2017 - 07/2010)
7.	Liu, Jing: 3 articles (11/2017 - 07/2010)
8.	Liu, Jun: 3 articles (11/2017 - 07/2010)
9.	Sun, Jiayi: 3 articles (11/2017 - 07/2010)
10.	Wang, Miao: 3 articles (11/2017 - 07/2010)

Related Diseases

1.	Insulin Resistance 09/28/2022 - "Furthermore, ST was more effective in improving blood glucose levels, insulin resistance indices, and very low-density lipoprotein cholesterol (VLDL-C) concentrations than RA. " 12/01/2013 - "In this animal model, supplementation with d-α-tocopherol improved insulin resistance as well as the serum levels of TG and very-low-density lipoprotein-cholesterol (VLDL-C) (P < 0.05). " 10/06/2014 - "No significant changes were found to total cholesterol, VLDL-c, fasting glucose, HbA1C, and insulin sensitivity index. " 01/01/2014 - "In 7-13-year-old children with BMI percentiles ranging from 0.1 to 99.6, the android/gynoid ratio was closely associated with insulin resistance and combined LDL + VLDL-cholesterol. " 12/01/2017 - "We found that probiotic supplementation among PCOS women for 12 weeks had favourable effects on weight loss, markers of insulin resistance, triglycerides and VLDL-cholesterol concentrations."
2.	Body Weight (Weight, Body) 01/01/2021 - "There were no significant changes in very-low-density lipoprotein cholesterol (VLDL-C) (ES: 0.13) levels, or body weights (ES: 0.51) (p > 0.05). " 11/22/2017 - "Compared with the control, EPS supplementation significantly reduced HF diet-induced body weight gain, adipose tissue weight, and plasma very-low-density lipoprotein cholesterol concentration (P < 0.05). " 03/24/2023 - "Under stress, the body weight gain, the concentrations of very low-density lipoprotein cholesterol and blood triglycerides decreased significantly. " 10/01/2007 - "There was a negative correlation between the body weight and HDL-cholesterol (r = -0.33, p < 0.01), a positive correlation between WHR and VLDL-cholesterol levels (r = 0.42, p < 0.01). " 04/01/1989 - "The cholesterol content of HDL and its subfractions is higher in women than in men and decreases with increasing serum VLDL-cholesterol level and body weight. "
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2019 - "Very low-density lipoprotein cholesterol is associated with extent and severity of coronary artery disease in patients with type 2 diabetes mellitus." 10/01/2014 - "Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides." 09/01/2014 - "Blood pressure, body mass index (BMI) and levels of HbA1c, FBG, TG, VLDL-cholesterol (VLDL-C), apoCIII and MAU were markedly elevated in the type 2 diabetes and type 2 DN groups compared with those in the control group (P<0.01), while high-density lipoprotein-cholesterol (HDL-C) levels were decreased significantly (P<0.01). " 04/01/2000 - "Type II (non-insulin-dependent) diabetes mellitus is associated with raised triglycerides and increased very low density lipoprotein cholesterol. " 01/01/2019 - "The plasma levels of very low-density lipoprotein cholesterol (p < 0.001) and triglycerides (p < 0.001) were also higher in coronary artery disease patients with type 2 diabetes mellitus than in coronary artery disease patients without type 2 diabetes mellitus. "
4.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2021 - "The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease." 07/01/2010 - "This study reports the association of VLDL cholesterol level and long-term CHD risk, as well as the combined effects of VLDL cholesterol and LDL cholesterol with other cardiovascular disease (CVD) risk factors. " 01/01/2021 - "We investigated the relationship between VLDL-cholesterol (VLDL-C) and recurrent major adverse cardiovascular events (MACE), major adverse limb events (MALE) and all-cause mortality in a cohort of patients with cardiovascular disease. " 05/11/2020 - "Association between Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Carotid Intima-Media Thickness in Postmenopausal Women Without Overt Cardiovascular Disease and on LDL-C Target Levels." 10/01/2008 - "High TG levels are a significant risk factor for cardiovascular disease and are a marker for atherogenic remnant lipo-proteins, such as very low-density lipoprotein cholesterol (VLDL-C). "
5.	Coronary Disease (Coronary Heart Disease) 07/01/2010 - "Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS)." 07/01/2010 - "Few studies have examined very-low-density lipoprotein (VLDL) cholesterol as an independent risk factor of coronary heart disease (CHD) or its combined effects with coexisting cardiac risk factors. " 11/01/2015 - "To evaluate the association between very low density lipoprotein cholesterol (VLDL-C) and cholesterol absorption and synthesis markers in patients with moderate and high risk of coronary heart disease. " 11/01/2015 - "[Association between very low density lipoprotein cholesterol and cholesterol absorption/synthesis markers in patients with moderate and high risk of coronary heart disease]." 11/15/2006 - "Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease."

Related Drugs and Biologics

1.	Triglycerides (Triacylglycerol)
2.	Cholesterol
3.	LDL Cholesterol
4.	HDL Cholesterol
5.	oxidized low density lipoprotein
6.	Lipids
7.	Insulin (Novolin)
8.	Glucose (Dextrose)
9.	Blood Glucose (Blood Sugar)
10.	VLDL Lipoproteins

Related Therapies and Procedures

1.	Therapeutics
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Aftercare (After-Treatment)
5.	Glycemic Control